Application of witch hazel tannin in preparation of medicine for treating muscular atrophy disease

By intervening with witch hazel tannin preparations, the problem of muscle atrophy caused by prolonged immobilization was resolved, muscle strength was restored and gastrocnemius muscle weight was increased, thus achieving an effective treatment for muscle atrophy.

CN118924729APending Publication Date: 2024-11-12SHANGHAI UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410977302.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Current technology lacks effective drug treatments to combat muscle atrophy caused by prolonged immobilization, and traditional rehabilitation measures can only relieve symptoms without providing a fundamental cure.

Method used

Using witch hazel tannin as the active ingredient, it is prepared in the form of tablets, granules, capsules, pills, oral liquids or injections to specifically intervene in the biological mechanism of muscle atrophy, restore muscle strength, increase the weight of the gastrocnemius muscle and the cross-sectional area of ​​muscle fibers, and inhibit the expression of muscle atrophy marker genes.

Benefits of technology

Witch hazel tannin significantly restores muscle strength, increases gastrocnemius muscle weight and muscle fiber cross-sectional area, while inhibiting the expression of muscle atrophy marker genes such as Atrogin-1 and MuRF-1, providing a more effective treatment for fixation-induced muscle atrophy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924729A_ABST
    Figure CN118924729A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and mainly relates to application of witch hazel tannin in preparation of a medicine for treating muscular atrophy diseases. According to the method, the muscular atrophy mouse model is constructed by inducing muscular atrophy through spiral line fixation, and the influence of the witch hazel tannin on the muscular strength, the gastrocnemius muscle weight and the gastrocnemius muscle fiber cross section area of the muscular atrophy mouse is observed. Results show that the witch hazel dannin can restore muscle strength, increase the gastrocnemius muscle weight and the gastrocnemius muscle fiber cross-sectional area, and inhibit expression of muscular atrophy symbolic genes at the same time. The hamamelis virginiana tannin can be used for effectively treating muscle atrophy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to the application of hamamelis tannin in the preparation of medicines for treating muscle atrophy diseases. Background Art

[0002] Muscle atrophy is a common health problem that is often caused by a variety of factors, including nerve damage, lack of exercise, and other underlying medical conditions. However, in some cases, muscle atrophy may be caused by prolonged immobilization of specific muscles. This immobilization can occur in bed rest, a fixed work environment, or other restrictive conditions. Currently, the treatment options for muscle atrophy caused by immobilization are relatively limited. Traditional rehabilitation measures may be able to relieve symptoms to a certain extent, but do not provide a fundamental cure. Therefore, there is an urgent need for a new treatment, particularly a drug therapy, to effectively combat muscle atrophy caused by immobilization.

[0003] Hamamelitannin is a polyphenol extracted from the bark of the witch hazel tree, with the structural formula shown in Formula (I). Hamamelitannin has been extensively studied and demonstrated to possess various biological activities, including cytotoxicity and anti-biofilm activity, as well as being a quorum sensing (QS) inhibitor. It increases the antibiotic susceptibility of Staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA release, and exhibits a high protective effect against peroxide-induced cell damage. However, prior research has not yet examined the correlation between hamamelitannin and muscle wasting diseases.

[0004] Summary of the Invention

[0005] In view of this, the object of the present invention is to provide the use of Hamamelis tannin in the preparation of a medicament for treating muscular atrophy diseases.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides application of Hamamelis tannin in preparing medicine for treating muscular atrophy disease.

[0008] Preferably, the muscle atrophy includes muscle atrophy caused by immobilization.

[0009] Preferably, the medicament is capable of restoring muscle strength.

[0010] Preferably, the drug can increase the weight of the gastrocnemius muscle

[0011] Preferably, the drug can increase the cross-sectional area of ​​gastrocnemius muscle fibers.

[0012] Preferably, the drug can reduce the expression of muscle atrophy marker genes.

[0013] Preferably, the muscle atrophy marker genes include Atrogin-1 and MuRF-1.

[0014] Preferably, the dosage form of the drug includes tablets, granules, capsules, pills, oral solutions or injections.

[0015] Preferably, the active ingredient of the drug is selected from one or more of Hamamelis tannin, isomers of Hamamelis tannin, pharmaceutically acceptable salts of Hamamelis tannin or pharmaceutically acceptable hydrates of Hamamelis tannin.

[0016] Preferably, the drug further comprises a pharmaceutically acceptable carrier.

[0017] Beneficial effects of the present invention:

[0018] This study, for the first time, proposes the use of witch hazel tannins in the preparation of a drug for treating muscular atrophy. This study used a mouse model of muscular atrophy induced by spiral fixation to investigate the effects of witch hazel tannins on muscle strength, gastrocnemius muscle weight, and cross-sectional area of ​​gastrocnemius fibers, as well as on the expression of genes that are hallmarks of muscular atrophy. The results demonstrated that witch hazel tannins restored muscle strength, increased gastrocnemius muscle weight and cross-sectional area, and inhibited the expression of genes that are hallmarks of muscular atrophy. This suggests that witch hazel tannins are effective in treating muscular atrophy.

[0019] The present invention provides a more effective and sustainable method for treating immobilization-induced muscle atrophy. By targeting specific biological mechanisms, the method can more effectively and harmlessly intervene in abnormal changes in muscle tissue, thereby significantly improving the treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of the experimental process for establishing a spiral wire fixation-induced muscle atrophy model in mice and treating it with witch hazel tannin via oral gavage.

[0021] Figure 2 The figure shows the effect of Hamamelis tannin on the muscle strength of mice with muscular atrophy; A is a statistical graph of the grip strength of the right hind limb of the mouse; B is a line graph of the contraction force of the right hind limb of the mouse.

[0022] Figure 3 This figure shows the improvement effect of Hamamelis tannin on the morphology and weight of the gastrocnemius muscle of mice with muscular atrophy; wherein, A is the morphological diagram of the gastrocnemius muscle of mice; B is the statistical diagram of the gastrocnemius muscle weight of mice.

[0023] Figure 4This is a diagram of WGA staining to detect the effect of Hamamelis tannin on the cross-sectional area of ​​gastrocnemius muscle fibers in mice with muscular atrophy; among them, A is the WGA staining image of the cross-sectional area of ​​gastrocnemius muscle fibers in mice; B is the statistical result of WGA staining of the cross-sectional area of ​​gastrocnemius muscle fibers in mice.

[0024] Figure 5 This figure shows the effect of Hamamelis tannin on the expression of muscle atrophy marker genes Atrogin-1 and MuRF-1 in the gastrocnemius muscle of muscular atrophy mice detected by fluorescence quantitative PCR; among them, A is the statistical graph of Atrogin-1 expression in the gastrocnemius muscle of mice; B is the statistical graph of MuRF-1 expression in the gastrocnemius muscle of mice. DETAILED DESCRIPTION

[0025] The present invention provides the use of witch hazel tannin in the preparation of a drug for treating muscular atrophy. Treatment of mice with muscular atrophy with witch hazel tannin restored muscle strength, increased gastrocnemius muscle weight and gastrocnemius fiber cross-sectional area, and inhibited the expression of genes that are hallmarks of muscle atrophy. This indicates that witch hazel tannin is effective in treating muscular atrophy.

[0026] The present invention has no particular limitation on the source of the Hamamelis tannin, and conventional commercial products in the field can be used. The structural formula of the Hamamelis tannin is shown in formula (I):

[0027]

[0028] Preferably, the muscle atrophy includes muscle atrophy caused by immobilization. The immobilization is preferably long-term immobilization of a specific muscle. The present invention has no particular limitation on the conditions under which immobilization occurs, and it can occur in bed rest, a fixed working environment, or other restrictive conditions.

[0029] Preferably, the drug is capable of restoring muscle strength; the muscle strength includes grip strength and contraction strength.

[0030] Preferably, the drug can increase the weight of the gastrocnemius muscle and the cross-sectional area of ​​the gastrocnemius muscle fibers.

[0031] Preferably, the drug can reduce the expression of muscle atrophy marker genes.

[0032] Preferably, the muscle atrophy marker genes include Atrogin-1 and MuRF-1.

[0033] Preferably, the dosage form of the drug includes tablets, granules, capsules, pills, oral solutions or injections.

[0034] Preferably, the active ingredient of the drug is selected from one or more of Hamamelis tannin, isomers of Hamamelis tannin, pharmaceutically acceptable salts of Hamamelis tannin, or pharmaceutically acceptable hydrates of Hamamelis tannin. The present invention has no particular limitation on the source of the above-mentioned compounds, and conventional commercial products in the art can be used.

[0035] Preferably, the drug further comprises a pharmaceutically acceptable carrier. The present invention does not specifically limit the types of pharmaceutically acceptable carriers, and any conventional pharmaceutically acceptable carriers in the art may be used, including but not limited to solvents, emulsifiers, disintegrants, fillers, binders, flavoring agents, colorants, and the like.

[0036] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0037] In the following examples, unless otherwise specified, all methods are conventional.

[0038] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0039] Example 1

[0040] Preparation of natural plant-derived product Witch Hazel Tannin:

[0041] Preparation of 0.5% CMC-Na solvent: Add 0.5g CMC-Na to 100ml of sterilized water at 70-80℃ and stir rapidly to make it swell. The undissolved part is sterilized and dissolved by high temperature and high pressure (121℃, 10min). After cooling, the obtained viscous solution is used to promote the dissolution of the compound Hamamelis tannin.

[0042] Finished product (purity 99.58%) Hamamelis tannin was purchased from Taoshu Biological. 1.25 mg of Hamamelis tannin was weighed and fully dissolved in 200 μl of 0.5% CMC-Na solvent to obtain Hamamelis tannin, which was set aside.

[0043] Example 2

[0044] Application of Hamamelis tannin in the treatment of immobilization-induced muscle atrophy

[0045] Experimental methods:

[0046] Establishment of a spiral wire immobilization (SWI) model in mice: Mice in the muscular atrophy model group were anesthetized with isoflurane and kept in the supine position. The hind limb hair was shaved with scissors, and the ankle joints were taped with medical bandages in a plantar flexed position. A 2.0 m / m steel wire was applied to the L4-5 spine and coiled around the hip joints and hind limbs for bilateral SWI. The hind limbs were fixed at right angles to the trunk at the hip joints. Mice in the muscular atrophy model control group received no treatment.

[0047] After 4 days of spiral fixation of the right hind limb of mice, mice with successfully constructed SWI muscle atrophy were treated with Hamamelis tannin via gavage for 4 weeks. Each mouse was given 50 mg / kg of tannin via gavage once a day. The placebo group was given the same volume of 0.5% CMC-Na (Vehicle). Evaluation and testing were performed after 4 weeks of treatment. Figure 1 The specific groups were: placebo group + muscle atrophy model control group, placebo group + muscle atrophy model group, witch hazel tannin group + muscle atrophy model control group, and witch hazel tannin group + muscle atrophy model group.

[0048] After the four-week treatment, the mice were tested for grip and contraction strength. The gastrocnemius muscles were then directly isolated and weighed using an electronic analytical balance. WGA staining was used to assess the cross-sectional area of ​​the gastrocnemius fibers. Finally, quantitative PCR was used to examine the expression of the muscle atrophy marker genes, Atrogin-1 and MuRF-1. This was done to determine whether Hamamelis tannins could treat immobilization-induced muscle atrophy.

[0049] Detection method and experimental results:

[0050] 1. Mouse Grip Strength Test: Place the mouse on the small animal grip strength meter for 5 minutes. Then, grasp the tail and pull horizontally at a constant speed. Record the maximum reading for all four legs. Repeat three times and take the average. Then, secure the right hind leg and test the grip strength of all three legs. Repeat three times and take the average. The final grip strength value for the right hind leg is the difference between the average grip strength of all four legs and the average grip strength of all three legs.

[0051] The experimental results are as follows Figure 2 As shown in A, the statistical results of the right hind limb grip strength of mice showed that after gavage with Hamamelis tannin, the right hind limb grip strength of mice with immobilization-induced muscle atrophy was improved compared with the placebo group.

[0052] 2. Mouse Contraction Force Measurement: Anesthetized mice were immobilized in the supine position. The distal tendon of the EDL muscle was isolated and tied to the lever arm of a dual-mode force transducer system equipped with a moving micrometer stage. The muscle was incubated at 37°C in oxygenated physiological saline solution [Krebs buffer: NaCl (137 × 10⁻³ M), KCl (5 × 10⁻³ M), CaCl₂ (2 × 10⁻³ M), MgSO₄ (1 × 10⁻³ M), NaH₂PO₄ (1 × 10⁻³ M), NaHCO₃ (24 × 10⁻³ M), glucose (11 × 10⁻³ M), pH = 7.35]. Prior to the experiment, the optimal muscle length was determined and recorded. Tetanic contractions were measured and controlled using dynamic muscle control software (Aurora Scientific, ASI600A) according to standard protocols. Tetanic contractions were performed with an initial delay of 0.5 s, a frequency of 120 Hz, and a duration of 0.3 s.

[0053] The experimental results are as follows Figure 2 As shown in B, the statistical results of the contraction force of the right hind limb of mice showed that after gavage with Hamamelis tannin, the contraction force of the right hind limb of mice with immobilization-induced muscle atrophy was improved compared with the placebo group.

[0054] 3. Observation of mouse gastrocnemius muscle morphology: The gastrocnemius muscle of mice was directly isolated after the experiment.

[0055] The experimental results are as follows Figure 3 As shown in A, the morphological observation of the gastrocnemius muscle showed that after mice were gavage-treated with Hamamelis tannin, the size of the gastrocnemius muscle of mice with immobilization-induced muscle atrophy was increased compared with the placebo group.

[0056] 4. Measurement of the weight of the gastrocnemius muscle of mice: Use an electronic analytical balance to detect the weight changes of the gastrocnemius muscle of mice.

[0057] The experimental results are as follows Figure 3 As shown in Figure B, electronic balance measurement found that after mice were gavage-treated with Hamamelis tannin, the weight of the gastrocnemius muscle of mice with immobilization-induced muscle atrophy was increased compared with the placebo group.

[0058] 5. Determination of the cross-sectional area of ​​mouse gastrocnemius muscle fibers:

[0059] Tissue WGA staining: OCT samples of mouse gastrocnemius muscle were frozen and sectioned at a thickness of 14 μm. The cut tissue was adsorbed onto adhesive slides and stored at -80°C until use. The specific WGA staining method is shown in Table 1:

[0060] Table 1 Specific method for WGA staining of mouse gastrocnemius muscle sections

[0061]

[0062] After washing with PBS buffer, 50% glycerol was added for sealing (protected from light), and photographed under a fluorescence microscope (CarlZeiss Microscopy GmbH), and then the cross-sectional area of ​​the mouse gastrocnemius muscle fibers was analyzed using ImageJ software.

[0063] The experimental results are as follows Figure 4 As shown, WGA staining and statistical results showed that after mice were gavage-treated with Hamamelis tannin, the cross-sectional area of ​​the gastrocnemius muscle fibers in mice with immobilization-induced muscle atrophy was increased compared with the placebo group.

[0064] 6. Determination of the expression levels of Atrogin-1 and MuRF-1, marker genes for gastrocnemius muscle atrophy in mice:

[0065] Fluorescence quantitative PCR: Total RNA was extracted from the gastrocnemius muscle of mice using the RNA extraction kit Total RNA Extraction Reagent, and RT-PCR and cDNA synthesis were performed using the SuperScript First-Strand Synthesis System. Quantitative experiments were then performed using the SYBR Green PCR kit, with 18S rRNA selected as the internal reference. -ΔΔCq The relative RNA levels were determined by qRT-PCR. The primer sequences used in qRT-PCR are as follows:

[0066] muu-Atrogin-1: Forward-CAGCTTCGTGAGCGACCTC (SEQ ID NO.1);

[0067] Reverse-GGCAGTCGAGAAGTCCAGTC (SEQ ID NO. 2). muu-MuRF-1: Forward-GTGTGAGGTGCCTACTTGCTC (SEQ ID NO.3);

[0068] Reverse-GCTCAGTCTTCTGTCCTGGA (SEQ ID NO. 4). mmu-18S: Forward-TCAAGAACGAAAGTCGGAGG (SEQ ID NO.5);

[0069] Reverse-GGACATCTAAGGGCATCAC (SEQ ID NO. 6).

[0070] The experimental results are as follows Figure 5 As shown, the results showed that after treatment with Hamamelis tannin, the expression of muscle atrophy marker genes Atrogin-1 and MuRF-1 in the gastrocnemius muscle of spiral fixed mice was reduced compared with the placebo group.

[0071] This study found that gavage of Hamamelis tannins to mice with immobilization-induced muscle atrophy effectively improved muscle atrophy. As a natural plant extract, Hamamelis tannins not only possess excellent biocompatibility and safety, but also offer an innovative and effective treatment approach by increasing muscle strength, increasing muscle fiber cross-sectional area, and reducing the expression of muscle atrophy marker genes. This approach holds promise for developing innovative drug therapies that could provide a more effective solution to muscle atrophy caused by immobilization.

[0072] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. Application of Hamamelis tannin in the preparation of drugs for the treatment of muscular atrophy.

2. The use according to claim 1, characterized in that: The muscle atrophy includes muscle atrophy caused by immobilization.

3. The use according to claim 1, characterized in that: The drug is able to restore muscle strength.

4. The use according to claim 1, characterized in that: The drug is capable of increasing gastrocnemius muscle weight.

5. The use according to claim 1, characterized in that: The drug is capable of increasing the cross-sectional area of ​​gastrocnemius muscle fibers.

6. The use according to claim 1, characterized in that: The drug can reduce the expression of muscle atrophy marker genes.

7. The use according to claim 6, characterized in that: The muscle atrophy marker genes include Atrogin-1 and MuRF-1.

8. The use according to any one of claims 1 to 7, characterized in that: The dosage form of the drug includes tablets, granules, capsules, pills, oral liquid or injection.

9. The use according to claim 8, characterized in that: The active ingredient of the drug is selected from one or more of Hamamelis tannin, isomers of Hamamelis tannin, pharmaceutically acceptable salts of Hamamelis tannin or pharmaceutically acceptable hydrates of Hamamelis tannin.

10. The use according to claim 9, characterized in that: The medicine also includes a pharmaceutically acceptable carrier.

Citation Information

Cited By

  • Application of avobenzone in preparation of animal intestinal atrophy model

    CN119632959A

  • Application of avobenzone in establishing an animal intestinal atrophy model

    CN119632959B